IGF-1 LR3 (long arginine 3, insulin-like growth factor 1) is a modified analog of naturally occurring IGF-1, engineered with an amino acid substitution and extension that reduces its binding to IGF-binding proteins — the proteins that normally clear IGF-1 from circulation quickly. The result, mechanistically, is a much longer active half-life than native IGF-1.
How It Differs From GH Secretagogues
Peptides like CJC-1295 and Ipamorelin work upstream — they stimulate the pituitary to release more of your own growth hormone, which the liver then converts into IGF-1. IGF-1 LR3 skips that entire cascade and acts directly at the IGF-1 receptor. That’s a fundamentally different intervention point, and it’s why the two categories aren’t interchangeable in research design even though they’re often discussed in the same conversations.
What the Extended Half-Life Means
Native IGF-1 has a half-life measured in minutes once it dissociates from its binding proteins. The LR3 modification extends that dramatically, which is precisely why it’s of research interest for sustained receptor engagement — but that same property is also why dosing precision and frequency matter more with this compound than with shorter-acting peptides.
A Note on Blood Glucose
Because IGF-1 shares structural and receptor overlap with insulin, its research use is closely tied to blood glucose regulation, and this is one of the more closely monitored variables in any protocol involving it. This is not a substance to approach casually.
Sourcing
IGF-1 LR3 is sold for research purposes only and is available through the following vendors.